All about this breast cancer subtype, how it behaves, and why there is cause for optimism
Key Takeaways
- Hormone receptor (HR)-positive breast cancer is the most common subtype and is driven by estrogen and progesterone hormones.
- Endocrine therapy blocks or lowers these hormones and is a highly effective targeted treatment.
- While HR-positive breast cancer often grows more slowly, it can return years after treatment, making long-term therapy and follow-up important.
- Ongoing research is advancing new treatments and improving outcomes, giving patients more options and better long-term prospects than ever before.
About 70% of breast cancers in women are hormone receptor (HR)-positive, making it the most common subtype. But even though it’s common, the diagnosis can still feel overwhelming. Thanks to research, including that of Breast Cancer Research Foundation (BCRF)-funded scientists, there has been significant progress in treatment and improving outcomes.
What is hormone receptor-positive breast cancer?
Hormone receptor (HR)-positive breast cancer is a subtype of the disease where cancer cells have receptors for estrogen, progesterone, or both. When these hormones bind to the receptors, they act like fuel, signaling cancer cells to grow and divide. Because the cancer depends on hormones to thrive, treatments that block or reduce hormone activity (known as endocrine therapy) are highly effective.
HR-positive breast cancers are classified based on the specific receptors found in tumor cells: estrogen receptors (ER), progesterone receptors (PR), or both. In ER-positive breast cancer, tumor cells have receptors that bind estrogen. When estrogen attaches to these receptors, it acts as a growth signal, telling cancer cells to multiply. Similarly, in PR-positive breast cancer, tumor cells respond to progesterone in the same way. Many HR-positive breast cancers are both ER- and PR-positive, meaning they are sensitive to both hormones. A tumor can also be ER-positive but PR-negative, or vice versa.
Because these cancers depend on hormones to grow, treatment focuses on disrupting that hormonal fuel supply. Hormone (endocrine) therapy such as tamoxifen (Nolvadex® or Soltamox®) or aromatase inhibitors work by either blocking hormone receptors or reducing hormone levels in the body. This targeted approach makes HR-positive breast cancer one of the most treatable subtypes, particularly when caught early.
How common is HR-positive breast cancer?
HR-positive breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancer diagnoses in women. In other words, the majority of people diagnosed with breast cancer have HR-positive tumors.
While HR-positive breast cancer can affect anyone, it is most commonly diagnosed in women, particularly those who are postmenopausal. Older age is one of the strongest risk factors, as estrogen exposure accumulates over a lifetime, increasing the likelihood that tumor cells will develop hormone sensitivity. HR-positive breast cancer also occurs in men, though breast cancer overall is far less common in men.
Understanding this subtype matters because it directly shapes treatment decisions for a large portion of patients. The fact that HR-positive tumors depend on hormones to grow means there are effective, well-established therapies—such as endocrine therapy—that can specifically target that dependency. For many patients, this classification is not just a diagnostic detail; it is the foundation of their entire treatment plan.
What makes HR-positive breast cancer different?
Not all breast cancers behave the same way, and what sets HR-positive breast cancer apart is its relationship with hormones. Unlike other subtypes, HR-positive tumors contain receptors inside the cancer cells that bind to estrogen, progesterone, or both. When these hormones connect with those receptors, they send signals that drive tumor growth. In effect, the cancer is using the body’s own hormonal activity as fuel.
This hormone dependency is what distinguishes HR-positive breast cancer biologically, but it also creates a clear treatment target. Because the tumor relies on hormones to grow, therapies designed to block or reduce that hormonal signal can be highly effective. This is in contrast to other subtypes, such as HR-negative/HER2-positive or triple-negative breast cancer, which do not respond to hormone-based treatments and require different approaches.
HR-positive breast cancer also tends to grow more slowly than some other subtypes, which is generally a favorable characteristic. However, it is important to note that HR-positive tumors can sometimes return years or even decades after initial treatment, a pattern known as late recurrence. This is one reason why long-term endocrine therapy is often recommended, even after early-stage treatment is complete.
In short, the hormone receptor status of a tumor is one of the most important factors in understanding how a breast cancer will behave, how it should be treated, and what to expect over time.
Treatment options for HR-positive breast cancer
Treatment for HR-positive breast cancer is often highly effective and tailored to the individual patient. It typically centers on hormone (endocrine) therapy, often combined with other targeted treatments, and may also include surgery, radiation therapy, or chemotherapy depending on the stage and characteristics of the cancer.
Hormone (endocrine) therapy
Hormone therapy works by either blocking estrogen from binding to those receptors or by reducing the amount of estrogen the body produces, effectively starving the cancer of the signal it needs to grow. There are three main classes of hormone therapy, each working through a distinct mechanism:
- Tamoxifen is a selective estrogen receptor modulator (SERM) that attaches to estrogen receptors in breast tissue and blocks estrogen from activating them. It is commonly prescribed for both pre- and post-menopausal patients.
- Aromatase inhibitors (AIs)—such as anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®)—suppress the enzyme aromatase that the body uses to produce estrogen. They are typically used in post-menopausal patients or those whose ovarian function has been suppressed.
- Selective estrogen receptor degraders (SERDs), such as fulvestrant (Faslodex®) and the newer oral agents elacestrant (Orserdu®) and imnulestrant (InluriyoTM), go a step further than SERMs. They not only block the estrogen receptor but actively break it down, reducing the number of receptors available in cancer cells. SERDs are particularly valuable in advanced (metastatic) settings and in cases where resistance to other hormone therapies has developed.
Because the goal of hormone therapy extends well beyond initial treatment, patients are generally advised to stay on them for an extended period—often five to 10 years—after primary treatment concludes. This tenure on the medications significantly reduces the risk of the cancer returning, either in the breast or elsewhere in the body, and is considered a critical part of long-term disease management.
Targeted therapies
For many patients with hormone receptor-positive breast cancer, hormone therapy alone may not provide sufficient protection against disease progression, particularly in advanced or metastatic cases. Other targeted therapies are designed to work alongside hormone therapy by interfering with specific molecular pathways that cancer cells rely on to grow and survive, offering a more precise attack on the disease than traditional chemotherapy.
One of the most significant advances in this area has been the development of CDK4/6 inhibitors—including palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®)—which block two proteins (cyclin-dependent kinases 4 and 6) that play a central role in driving cell division, which may lead to cancer growth. By halting this process, these drugs can slow or stop tumor growth. They are typically used in combination with an aromatase inhibitor or fulvestrant and have become a standard-of-care for many patients with advanced HR-positive, HER2-negative breast cancer.
Other notable targeted therapy classes include:
- PI3K inhibitors (such as alpelisib (Vijoice®)), which target a common mutation found in some HR-positive cancers.
- mTOR inhibitors (such as everolimus (Afinitor® or Zortress®)), which block a signaling pathway that can fuel resistance to hormone therapy.
- Antibody-drug conjugates (ADCs), each with a distinct molecular architecture: sacituzumab govitecan (Trodelvy®) and datopotamab-durextecan (Datroway®) which are TROP2-directed ADCs; and trastuzumab deruxtecan (Enhertu®) which is HER2-directed. These ADCs are approved for patients with HR-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
The ADC space for HR-positive breast cancer has moved quickly, with three approvals in just over two years—a cause for optimism.
Adding targeted therapies to hormone therapy regimens has meaningfully improved outcomes for many patients. Clinical trials have demonstrated significant gains in progression-free survival, and in some cases overall survival, compared to hormone therapy alone. For patients with metastatic disease in particular, these combinations have helped transform what was once a rapidly progressing condition into one that can often be managed over a longer period of time.
Chemotherapy and when it’s used
Unlike some other breast cancer subtypes, chemotherapy is not a requirement for HR-positive breast cancer. Because HR-positive tumors often respond well to hormone therapy and other targeted treatments, many patients can be effectively treated without chemotherapy. And for those with early-stage, low-risk disease, the potential side effects may outweigh any additional benefit it would provide.
That said, chemotherapy remains an important option in certain situations. It is more likely to be recommended when the cancer is diagnosed at a later stage, when the tumor is large, when lymph nodes are involved, or when other high-risk features are present. Genomic testing tools—such as the Oncotype DX, MammaPrint, and Prosigna assays—can help guide this decision by analyzing the activity of specific genes within the tumor to estimate the likelihood of recurrence and the potential benefit of chemotherapy. In cases where the cancer shows aggressive characteristics, has not responded adequately to hormone therapy, or has spread beyond the breast, chemotherapy may be added to the treatment plan to improve outcomes.
When chemotherapy is used, it is typically one component of a broader, multi-pronged approach rather than a standalone treatment. It may be administered before surgery (neoadjuvant) to shrink a tumor, or after surgery (adjuvant) to reduce the risk of recurrence, and is generally coordinated alongside hormone therapy, other targeted therapies, and other interventions as appropriate to the individual patient’s situation.
The latest research and advances—and a breakthrough in hormone therapy
The treatment of HR-positive breast cancer has long relied on a limited toolkit and, for more than two decades, fulvestrant (administered by injection) was the only SERD available to patients. In 2023, elacestrant was the first SERD to gain approval in over 20 years, with the added advantage of oral administration. Since then, imlunestrant has followed as a second FDA-approved oral SERD — a meaningful shift in what is available to patients, particularly those with advanced or treatment-resistant disease.
Generally, SERDs are well tolerated, particularly the newer oral agents, and have a favorable safety profile relative to chemotherapy. This means that most patients feel well enough to stay on treatment. But side effects do vary by drug and combination, and individual patient factors matter. So, the picture is a bit nuanced depending on which SERD and what combination of therapies are being used.
ADCs are another example of how newer drug classes are broadening options for patients with advanced disease.
Approval of oral SERDs and ADCs are milestones that are part of a broader wave of progress across HR-positive breast cancer research. Recent positive results from clinical trials testing next-generation oral SERDs both alone and in combination with other therapies such as CDK4/6 inhibitors offer promise in overcoming treatment resistance, one of the most persistent challenges in managing this disease. ER-positive breast cancers require long-term follow-up five to 10 or more years because the risk of late recurrence persists, which makes advances in both treatment and recurrence prediction especially consequential for patients.
Progress like this does not happen by chance—it is the direct result of sustained investment in scientific research, including foundational studies, clinical trials, and investigator-led studies funded by organizations like BCRF.
Why there is good news for HR-positive breast cancer
For those diagnosed with HR-positive breast cancer today, the treatment landscape looks meaningfully different—and more hopeful—than it did even a decade ago. Patients now have access to more options than ever before, with therapies that are increasingly precise in how they target the disease and more manageable in terms of side effects and quality of life during and after treatment.
The advancements reflect a field in genuine forward motion. Targeted hormone therapy remains a highly effective cornerstone of care, and the expansion of the SERD class of drugs—from a single injectable option to multiple oral agents—gives patients and their doctors greater flexibility in tailoring treatment to individual circumstances. Targeted therapies like ADCs and CDK4/6 inhibitors have further raised the bar, improving outcomes for many patients with advanced disease and helping to extend the period in which the cancer can be effectively controlled. For patients facing the challenge of treatment resistance—one of the most difficult aspects of managing this disease long term—newer drug combinations and next-generation agents are beginning to provide real answers.
Outcomes for HR-positive breast cancer continue to improve, and this subtype remains one of the most treatable forms of the disease. Its typically slower growth and strong responsiveness to hormone-based therapies mean that, for many patients, it can be managed over the long term with a sustained focus on preventing recurrence and maintaining quality of life. Research into late recurrence, resistance mechanisms, and individualized treatment strategies is actively addressing the areas where gaps have historically remained.
Moving forward: The role of research
None of this progress has happened in isolation. It is the product of decades of sustained scientific investment—through clinical trials, laboratory research, and the work of dedicated investigators supported by organizations like BCRF. Our investigators have been instrumental in the development and testing of SERDs, SERMS, CDK4/6 inhibitors, and most recently ADCs for treating HR-positive breast cancer. In addition, they are conducting research that is key to improving survival and quality of life.
HR-positive breast cancer is one of the most studied and most treatable forms of breast cancer—and the pace of progress shows no signs of slowing. From the foundational discoveries that first identified the role of estrogen in cancer growth, to the development of tamoxifen, to the recent approval of new oral SERDs, each advance has built on the last. The field is not standing still, and neither is the science.
For patients navigating a diagnosis today, that trajectory matters. More targeted treatments, smarter combinations, better tools for predicting and preventing recurrence, and a growing understanding of how to overcome resistance are not distant possibilities. Many are already available, and more are on the way.
The goal has always been the same: to give every patient the best possible chance at a long, healthy life. Research is how we get there—one trial, one discovery, one breakthrough at a time.
Frequently Asked Questions
Can hormone receptor-positive breast cancer be cured?
Many cases of HR-positive breast cancer can be treated successfully, especially when diagnosed early. Outcomes depend on factors like stage, tumor biology, and response to therapy. While some patients may be considered cancer-free after treatment, long-term follow-up is important because HR-positive breast cancer can recur years later.
Is HR-positive breast cancer aggressive?
HR-positive breast cancer is often slower-growing than some other subtypes. However, it can carry a risk of recurrence over a longer period, which is why ongoing treatment and monitoring are important parts of care.
How long do you need hormone therapy for HR-positive breast cancer?
Hormone (endocrine) therapy is often recommended for 5 to 10 years, depending on individual risk factors and treatment response. This long-term approach helps reduce the risk of recurrence, particularly crucial for HR-positive cancers which can return years after initial treatment.
What are the latest treatments for HR-positive breast cancer?
Recent advances include next-generation hormone therapies, targeted treatments used alongside endocrine therapy, and new approaches to overcoming treatment resistance. Researchers are also exploring ways to better predict recurrence risk and personalize treatment using advanced tools and data.
Can HR-positive breast cancer come back after treatment?
Yes, HR-positive breast cancer can recur, sometimes many years after initial treatment. However, long-term therapies like hormone treatment and ongoing monitoring significantly reduce this risk and help manage the disease effectively.
